Thermo Fisher Scientific SPG11 Recombinant Superclonal Antibody (2HCLC)

Applications

Western Blot (WB)

• Tested Dilution: 1:200

Immunocytochemistry (ICC/IF)

• Tested Dilution: 5 µg/mL

Product Specifications

Product Specific Information

This antibody is predicted to react with Monkey, Horse, Bovine, and Sheep.

Recombinant rabbit Superclonal™ antibodies are unique offerings from Thermo Fisher Scientific. They consist of multiple different recombinant monoclonal antibodies, combining the sensitivity of polyclonal antibodies with the specificity of monoclonal antibodies. Each lot maintains consistent performance due to controlled recombinant production, eliminating variability typical of polyclonal antibodies.

Formerly called “Recombinant polyclonal antibody”, this product is now rebranded as “Recombinant Superclonal™ antibody”. The physical product and performance remain unchanged.

Target Information

Hereditary spastic paraplegias (HSPs) are genetically and phenotypically heterogeneous disorders. Spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC) is a frequent form of complicated hereditary spastic paraplegia (cHSP), characterized by mental retardation and muscle stiffness at onset, followed by progressive paraparesis and cognitive decline.

Mutations of the SPG11 gene encoding the spatacsin protein are a major cause of HSP-TCC. Spatacsin is a potential transmembrane protein phosphorylated upon DNA damage and expressed throughout the brain, with high levels in the cerebellum. SPG11 mutations are more frequent in familial than sporadic forms of cHSP without TCC.

Kjellin syndrome is associated with mutations in both SPG15 and SPG11 genes. Recent studies suggest that Parkinsonism may initiate SPG11-linked HSP TCC and that SPG11 mutations can cause juvenile Parkinsonism.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.